Journal
ONCOLOGY REVIEWS
Volume 10, Issue 2, Pages 54-59Publisher
PAGEPRESS PUBL
DOI: 10.4081/oncol.2016.298
Keywords
Hypertension; angiotensin system inhibitors; renal cell carcinoma; renin-angiotensin system
Categories
Ask authors/readers for more resources
Arterial hypertension (HTN) is a class effect of anti vascular endothelial growth factor (VEGF) therapies, including the monoclonal antibody bevacizumab. Data are conflicting regarding the role of the renin-angiotensin system on angiogenesis and recent data suggest that the use of angiotensin system inhibitors (ASIs; angiotensin receptor blockers or angiotensin-converting enzyme inhibitors) is associated with improved survival in metastatic renal cell carcinoma (mRCC), particularly when used with VEGF targeted therapies. The aim of this review is to discuss the available treatment options for mRCC and associated incidence of hypertension as well as summarize the known data about ASIs use and mRCC. Additionally, given that the optimal management of HTN remains unclear, we will focus on prevention strategies and propose potential therapeutic approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available